Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14921743 | 0.93 | SMN1; SMN2 (0.39) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL319860 | 0.90 | NPC1 (0.39) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16187171 | 0.85 | MEN1 (0.33) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16757254 | 0.85 | MEN1 (0.38) | SMN1; SMN2MEN1KMT2ASCN9AALDH1A1 | |
| SCHEMBL17048546 | 0.83 | MEN1 (0.40) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18983167 | 0.83 | CNR1 (0.38) | SMN1; SMN2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL9924609 | 0.83 | SCN9A (0.41) | SMN1; SMN2MEN1KMT2ASCN9AALDH1A1 | |
| SCHEMBL17048652 | 0.83 | SCN9A (0.37) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL319968 | 0.82 | NPC1 (0.35) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18882670 | 0.82 | SCN9A (0.35) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3144300-B1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | DAIICHI SANKYO CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9845313-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-19 | — | — | US | disclosed |
| EP-3144300-A1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | Daiichi Sankyo Company, Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9493448-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| EP-2813491-B1 | CYCLOALKANE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| EP-2813491-A1 | CYCLOALKANE DERIVATIVE | Daiichi Sankyo Co., Ltd. (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SMN1; SMN2 86/4885NPC1 3772/4885RAB9A 4083/4885 |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | TRPV1, TRPA1, SCNN1A | SMN1; SMN2 1785/4885NPC1 329/4885RAB9A 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.